文献速递白血病造血干细胞移植与细胞治疗

CD19/CD22双靶点CAR-T治疗B-ALL复发机制解读

Unraveling cellular and molecular mechanisms of relapse in CD19/CD22 dual-targeting chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia.
PubMed 文献 · Leukemia · 2026-05-29

该研究分析91例接受CD19/CD22双靶点CAR-T治疗的B-ALL患者,完全缓解率91.9%,应答者中32.9%复发,中位约7个月。CAR-T功能不足是晚期复发主因(92.3%),早期复发异质性大,PAX5突变导致CD19/CD22下调是早期复发的新机制。

要点

  • CAR-T功能不足是复发最常见驱动因素(61.5%),抗原不足次之(15.4%)。
  • 晚期复发(>7个月)中92.3%为CAR-T功能不足,表现为持续性缺失或CD19⁺B细胞恢复。
  • PAX5破坏性突变通过降低CD19/CD22表达导致早期复发,需考虑靶向策略。

核心结论

  • CAR-T功能不足和抗原不足是CD19/CD22双靶点CAR-T治疗后复发的主要驱动因素。
  • PAX5破坏性突变定义了早期复发的一种独特分子机制。

研究设计与样本

  • 研究纳入91例接受CD19/CD22双靶点CAR-T治疗的B-ALL患者(临床试验ChiCTR-OPN-16008526)。
  • 评估复发情况并进行机制分析。

主要发现

  • 完全缓解率为91.9%。
  • 应答者中32.9%(26/79)复发,中位复发时间约7个月。
  • 晚期复发(>7个月)中92.3%为CAR-T功能不足,表现为持续性缺失或CD19⁺B淋巴细胞恢复。
  • 早期复发异质性较大,30.8%归因于CAR-T功能不足,30.8%归因于抗原不足。
  • 两例早期复发(15.4%)显示CD19/CD22同时下调,并携带预先存在的PAX5缺失或移码插入。

临床怎么用

  • 监测CAR-T持久性和B细胞恢复有助于预测晚期复发。
  • 对早期复发患者应评估PAX5突变及CD19/CD22表达下调。
  • PAX5突变提示可能需要靶向策略以克服耐药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD19/CD22 dual-target chimeric antigen receptor (CAR19/22) T cell therapies mark a key advance over single-target options for refractory B-cell malignancies. However, over 20% of patients relapse and underlying mechanisms remain less understood. This study evaluated relapse in 91 B-cell acute lymphoblastic leukemia (B-ALL) patients treated with CAR19/22 T cells a clinical trial (ChiCTR-OPN-16008526). The complete remission rate was 91.9%, and 32.9% (26/79) of responders relapsed at a median of approximately 7 months. Among late relapses (>7 months), 92.3% was CAR T functional insufficiency showing lack of persistence or recovery of CD19⁺ B lymphocytes. Early relapses showed greater heterogeneity with 30.8% attributable to CAR T functional insufficiency and 30.8% to antigen insufficiency. Notably, two early relapses (15.4%) exhibited concurrent CD19/CD22 downregulation and harbored a preexisting PAX5 deletion or frameshift insertion. These PAX5-mutated subclones persisted and expanded at relapse, with one patient acquiring additional CD19 mutations. PAX5 knockout in leukemic cells reduced CD19/CD22 expression and proximal enhancer activities, causing in vitro resistance to CAR19/22 T cells. Collectively, CAR T functional insufficiency and antigen insufficiency are the most (61.5%) and second (15.4%) frequent drivers of relapse, respectively. Disruptive PAX5 mutations define a distinct molecular mechanism of early relapse, guiding rational targeted strategies.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Tan J, He F, Hu H, et al. Unraveling cellular and molecular mechanisms of relapse in CD19/CD22 dual-targeting chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia. Leukemia. 2026. PMID: 42215727. doi:10.1038/s41375-026-02978-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。